Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2009

Siemens and Sysmex Ink Five-Year Deal Extension

  • Siemens Healthcare and Sysmex will continue to jointly supply and develop coagulation instruments and tests for another five years. The contract renewal covers global distributorship, sales, and services as well as further development activities.

    The wide variety of coagulation instruments and tests covered in this agreement are used by clinical laboratories to test for blood disorders in patients or to monitor patients on blood-thinning medication. The agreement also includes access to automated platelet function testing.

    Commenting on the 14-year collaboration, Sysmex CEO and president, Hisashi Ietsugu, says, "Our partnership combines the strengths of two leading diagnostic companies whose joint expertise offers best-in-class solutions for the laboratory, and we look forward to expanding the clinical utility of these solutions cooperatively."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »